Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir

Coronavirus disease 2019 (COVID‐19) is a continued leading cause of hospitalization and death. Safe, efficacious COVID‐19 antivirals are needed urgently. Nirmatrelvir (PF‐07321332), the first orally bioavailable, severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) M(pro) inhibitor against t...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Ravi Shankar P., Toussi, Sima S., Hackman, Frances, Chan, Phylinda L., Rao, Rohit, Allen, Richard, Van Eyck, Lien, Pawlak, Sylvester, Kadar, Eugene P., Clark, Frances, Shi, Haihong, Anderson, Annaliesa S., Binks, Michael, Menon, Sandeep, Nucci, Gianluca, Bergman, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087011/
https://www.ncbi.nlm.nih.gov/pubmed/35388471
http://dx.doi.org/10.1002/cpt.2603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087011/
https://www.ncbi.nlm.nih.gov/pubmed/35388471
http://dx.doi.org/10.1002/cpt.2603

Ejemplares similares